Financial·Reported by 12 outside sources·
A Reuters study published on August 31, 2026, found that patients on low-dose GLP-1 weight-loss drugs still lose weight but less than at full doses, with Eli Lilly's tirzepatide showing better results than Novo Nordisk's semaglutide.
- Who
- Eli Lilly and Company, Novo Nordisk A/S
- Where
- United States
- When
- Why
- To inform investors and patients about competitive dynamics, efficacy differences, and market implications of low-dose GLP-1 treatments.
via marketaux